Research
Current variables, definitions and endpoints of the European Cardiovascular Magnetic Resonance Registry
-
* Corresponding author: Anja Wagner anja.wagner@gmail.com
1 Department of Cardiology, Hahnemann University Hospital, Drexel University College of Medicine, Philadelphia, USA
2 Department of Cardiology and Angiology, Elisabeth Hospital, Essen, Germany
3 Institut für Herzinfarktforschung, Ludwigshafen, Germany
4 Department of Cardiology, Klinikum Ludwigsburg, Ludwigsburg, Germany
5 Department of Cardiology, University Hospital Basel, Basel, Switzerland
6 Cardiac Imaging Unit, Hospital de la Santa Creu I Sant Pau, Universitat Autonoma de Barcelona, Spain
7 Department of Cardiology, Kerkhoff-Klinik, Bad Nauheim, Germany
8 Department of Internal Medicine II, Cardiology, University of Ulm, Ulm, Germany
9 Clinical Physiology Institute, CNR National Research Council, Pisa, Italy
10 Department of Cardiology, VU Medical Centre, Amsterdam, The Netherlands
11 Cardiac MR Centre, University Hospital Lausanne, Lausanne, Switzerland
12 Department of Cardiology, Robert Bosch Medical Centre, Stuttgart, Germany
13 Division of Imaging Sciences, King's College London BHF Centre of Excellence and NIHR Biomedical Research Centre, St Thomas' Trust, London, UK
Journal of Cardiovascular Magnetic Resonance 2009, 11:43 doi:10.1186/1532-429X-11-43
Published: 5 November 2009Abstract
Background
Cardiovascular Magnetic Resonance (CMR) is increasingly used in daily clinical practice. However, little is known about its clinical utility such as image quality, safety and impact on patient management. In addition, there is limited information about the potential of CMR to acquire prognostic information.
Methods
The European Cardiovascular Magnetic Resonance Registry (EuroCMR Registry) will consist of two parts: 1) Multicenter registry with consecutive enrolment of patients scanned in all participating European CMR centres using web based online case record forms. 2) Prospective clinical follow up of patients with suspected coronary artery disease (CAD) and hypertrophic cardiomyopathy (HCM) every 12 months after enrolment to assess prognostic data.
Conclusion
The EuroCMR Registry offers an opportunity to provide information about the clinical utility of routine CMR in a large number of cases and a diverse population. Furthermore it has the potential to gather information about the prognostic value of CMR in specific patient populations.